| tenofovir disoproxil fumarate / Generic mfg. |
ChiCTR-IIR-16007988: An open label, randomized, single-dose, two-period, two-sequence, crossover pivotal study to assess the bioequivalence of Tenofovir Disoproxil Fumarate Tablets 300mg in healthy adult subjects under fasting/ Fed condition |
|
|
| Recruiting | 1 | 26 | | Phase 1 take test preparation on an empty stomach; Phase 2 take control product on an empty stomach; Phase 3 take test preparation after meal; Phase 4 take control product after meal. ;Phase 1 take control product on an empty stomach; Phase 2 take test preparation on an empty stomach; Phase 3 take control product after meal; Phase 4 take test preparation after meal. | The first hospital of jilin university; Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd | HBV、HIV-1 infection | | | | |
NCT00024986: Tenofovir Disoproxil Fumarate to Treat Pediatric HIV |
|
|
| Completed | 1 | 30 | US | Tenofovir DF | National Cancer Institute (NCI) | HIV Infection | | 09/05 | | |
NCT00828789: VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer |
|
|
| Completed | 1 | 20 | RoW | Efavirenz; Tenofovir disoproxil fumarate; Telaprevir | Tibotec BVBA | Hepatitis C, HCV, HIV, AIDS | 04/09 | 04/09 | | |
| Completed | 1 | 24 | US | Tenofovir Disoproxil Fumarate, Viread, Tenofovir | Public Health Foundation Enterprises, Inc., National Institute of Mental Health (NIMH) | HIV | 06/10 | 06/10 | | |
NCT00120471: Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies |
|
|
| Completed | 1 | 122 | RoW | Tenofovir disoproxil fumarate, TDF | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH) | HIV Infections | 10/11 | 12/11 | | |
NCT02039323: A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants |
|
|
| Completed | 1 | 6 | US | Tenofovir, Tenofovir disoproxil fumurate, Viread, Maraviroc, Selzentry | University of North Carolina, Chapel Hill | Healthy Adult Females | 04/14 | 04/14 | | |
NCT02006264: Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring |
|
|
| Completed | 1 | 30 | US | TDF Intravaginal Ring, TDF IVR, Placebo Intravaginal Ring, Placebo | Albert Einstein College of Medicine, National Institute of Allergy and Infectious Diseases (NIAID) | HIV | 11/14 | 11/14 | | |
2016-004392-41: Adult Lamivudine and Tenofovir Biocomparison Study for Pediatric Fixed Dose Combination Formulation |
|
|
| | 1 | 24 | Canada | Lamivudine, Lamivudine - uncoated granules - 300 mg, Lamivudine - coated granules -300 mg, VIREAD, tenofovir disoproxil fumarate - uncoated granules - 300 mg, tenofovir disoproxil fumarate - coated granules - 300 mg, Tablet, Granules, 3TC® (Lamivudine), VIREAD® (tenofovir disoproxil fumarate) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | HIV-1 infection, HIV-1 infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT02762617: Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002) |
|
|
| Terminated | 1 | 17 | US, RoW | Tenofovir disoproxil fumarate intravaginal ring, TDF IVR, Placebo intravaginal ring (IVR), Placebo | Marla Keller, National Institute of Allergy and Infectious Diseases (NIAID) | Healthy, HIV | 10/17 | 10/17 | | |
